Martin et. al. Heart disease and stroke statistics: a report of U.S. and global data from the American Heart Association. Circulation 2024. https://doi.org/10.1161/CIR.0000000000001209

Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–58. https://doi.org/10.4239/wjd.v6.i13.1246.PMID:26468341;PMCID:PMC4600176.

Article  PubMed  PubMed Central  Google Scholar 

Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–94. https://doi.org/10.1161/circulationaha.122.059595.

Article  CAS  PubMed  Google Scholar 

American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103–23. https://doi.org/10.2337/dc19-S010.

Article  Google Scholar 

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.

Article  PubMed  Google Scholar 

Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 25 May 2025.

Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Investig. 2014;124(10):4223–6. https://doi.org/10.1172/JCI78371.

Article  PubMed  PubMed Central  Google Scholar 

Shchendrygina A, Rakisheva A, Giverts I, Rustamova Y, Soloveva A. Effects of glucagonlike peptide-1 receptor agonists on cardiac function exercise capacity and quality of life. Cardiac Failure Review. 2024;10. https://doi.org/10.15420/cfr.2024.05.

Liu Q K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15. https://doi.org/10.3389/fendo.2024.1431292

Dhindsa DS, Mehta A, Sandesara PB, et al. Strategies for appropriate selection of SGLT2-i vs. GLP1-RA in persons with diabetes and cardiovascular disease. Curr Cardiol Rep. 2019;21:100. https://doi.org/10.1007/s11886-019-1197-6.

Article  PubMed  Google Scholar 

Ferrannini G, Mellbin LG, Kirabo F, Ramasundarahettige C, Gerstein HC, Rydén L.  Dulaglutide and a composite outcome reflecting atherosclerosis in the REWIND trial: a post hoc analysis. Diabetes Care. 2022;45(10):e146–7. https://doi.org/10.2337/dc22-0903.

Article  PubMed  Google Scholar 

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Hernandez, Adrian FDel Prato, Stefano et al. The Lancet 392(10157):1519-1529

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. https://doi.org/10.1056/nejmoa2108269.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/nejmoa2307563.

Article  CAS  PubMed  Google Scholar 

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024. https://doi.org/10.1056/nejmoa2410027.

Article  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/nejmoa1504720.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/nejmoa1611925.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/nejmoa1812389.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna A, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky  V, Merkely B. Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, MC Petrie. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389(12):1069–1084. https://doi.org/10.1056/NEJMoa2306963.

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, La Brunner- Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/nejmoa2022190.

Article  CAS  PubMed  Google Scholar 

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology. 2018;6(8):605–617. https://doi.org/10.1016/S2213-8587(18)30104-9.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/nejmoa1911303.

Article  CAS  PubMed  Google Scholar 

Empagliflozin in patients with chronic kidney disease. (2023). New England J Med 388(2):117–127. https://doi.org/10.1056/nejmoa2204233

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/nejmoa1811744.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/nejmoa2024816.

Article  CAS  PubMed  Google Scholar 

Artigas CF, Stokes V, Tan GD, Theodorakis MJ. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice. Expert Opin Pharmacother. 2015;16(10):1417–21. https://doi.org/10.1517/14656566.2015.1052740.

Article  CAS  PubMed  Google Scholar 

Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V. Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment. J Am Heart Assoc. 2020. https://doi.org/10.1161/jaha.119.015716.

Article  PubMed  PubMed Central  Google Scholar 

Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients? J Clin Med Res. 2014;6(2):138–44. https://doi.org/10.14740/jocmr1719w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruinstroop E, Meyer L, Brouwer CB, van Rooijen DE, van Dam PS. Retrospective analysis of an insulin-to-liraglutide switch in patients with type 2 diabetes mellitus. Diabetes Ther. 2018;9(3):1369–75. https://doi.org/10.1007/s13300-018-0438-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta R, Billings LK, Liebl A, Vilsbøll T. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes. Diabet Med. 2022;39(9). https://doi.org/10.1111/dme.14901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Nino A, Soffer J, et al. Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care. 2020;43:2509–18.

CAS  PubMed  PubMed Central